Actinium Pharmaceuticals Inc ATNM:NYSE American

Last Price$0.27Cboe Real-Time Last Sale as of 12:32PM ET 6/17/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.03(10.66%)
Bid (Size)$0.26 (100)
Ask (Size)$0.27 (200)
Day Low / High$0.24 - 0.27
Volume668.1 K

View Biotechnology IndustryPeer Comparison as of 06/17/2019


Actinium Pharmaceuticals Inc ( NYSE MKT LLC )

Price: $0.27
Change: +0.03 (10.66%)
Volume: 668.1 K
12:32PM ET 6/17/2019

Bio Path Holdings Inc ( NASDAQ )

Price: $14.25
Change: +0.23 (1.64%)
Volume: 29.9 K
12:08PM ET 6/17/2019

Aptevo Therapeutics Inc ( NASDAQ )

Price: $0.90
Change: +0.02 (2.21%)
Volume: 238.7 K
12:22PM ET 6/17/2019

Cidara Therapeutics Inc ( NASDAQ )

Price: $1.67
Change: +0.13 (8.44%)
Volume: 107.6 K
12:32PM ET 6/17/2019

Innovate Biopharmaceuticals Inc ( NASDAQ )

Price: $1.14
Change: -0.04 (3.39%)
Volume: 153.5 K
12:21PM ET 6/17/2019

Read more news Recent News

Actinium Reports Positive Data About Leukemia Drug for Older Patients
9:59AM ET 6/04/2019 MT Newswires

Actinium Pharmaceuticals (ATNM) on Tuesday shared positive data from the ongoing phase 3 SIERRA study of Iomab-B's single agent effect in patients with...

Wall Street Set for Rebound After Tech Fallout
9:03AM ET 6/04/2019 MT Newswires

US stocks were set for an upbeat open Tuesday as markets recover after the tech-heavy Nasdaq Composite index closed nearly 2% lower on Monday on concerns...

--Analyst Actions: Oppenheimer Cuts Actinium Pharma PT to $4 from $5 on Dilutive Impact from Recent Share Offer, Keeps at Outperform - Stock Up 1%
2:06PM ET 5/28/2019 MT Newswires

Price: 0.30, Change: +0.01, Percent Change: +1.87 ...

Stock Move: Actinium Shares Dive 32% After Pricing of $16.5 Mln Offering of Stock, Warrants
12:08PM ET 4/18/2019 MT Newswires

Actinium Pharmaceuticals (ATNM) shares were 32% lower Thursday at midday after the biotechnology company priced 42.9 million shares of its common stock and...

Company Profile

Business DescriptionActinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY. View company web site for more details
Address275 Madison Avenue
New York, New York 10016
Number of Employees30
Recent SEC Filing06/07/20198-K
Executive Chairman & Chief Executive OfficerSandesh Seth
Principal Financial & Accounting OfficerSteve Oloughlin
Chief Medical OfficerMark S. Berger
Chief Scientific OfficerDale L. Ludwig

Company Highlights

Price Open$0.25
Previous Close$0.24
52 Week Range$0.23 - 0.87
Market Capitalization$43.7 M
Shares Outstanding162.0 M
SectorHealth Technology
Next Earnings Announcement08/08/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.20
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-213.70%

Analyst Ratings as of 06/07/2019

Consensus RecommendationConsensus Icon
Powered by Factset